Heffter co-founder David Nichols has an “Editors Pick” article on reset.me, a new web site devoted to journalism on psychedelics and related topics. In “When Will Medicinal ‘Magic Mushrooms’ Be Legalized?” Dr. Nichols gives an overview of Heffter-sponsored research using psilocybin to treat addiction, anxiety,...
An article in the New York Times “Fashion and Style” section covers the current popularity of the psychedelic beverage ayahuasca. The article features quotes from Heffter board member Charles Grob.“‘It”s a fascinating compound with a great deal to be learned from its effects,’ said Dr....
A new study uses fMRI technology to distinguish the effects of MDMA (“Ecstasy”) and the classic psychedelic psilocybin on the networks within the brain. Researchers found that psilocybin produces unique changes in consciousness.The effects of psilocybin and MDMA on between-network resting state functional connectivity in...
The Purdue University independent daily student newspaper, The Exponent, has a featured article about Heffter’s President and co-founder Dr. David Nichols.AP photoby Reed Sellers“A former Purdue professor is making major headway in a revolutionary method of treatment for psychiatric disorders by facilitating controlled psychedelic trips.“Adjunct...
We’re saddened to note the passing of Dr. Alexander “Sasha” Shulgin, an important pioneer of psychedelic chemistry. In addition to a long and remarkably productive career as a chemist, Dr. Shulgin authored a number of influential books including two scientific autobiographies, PIHKAL: A Chemical Love...
